Prof. Keith Roberts, Consultant Hepatobiliary, Pancreatic and Liver Transplant Surgeon

Prof. Keith Roberts

Consultant Hepatobiliary, Pancreatic and Liver Transplant Surgeon

Book online
|

Prof. Keith Roberts PhD FRCS

Consultant Hepatobiliary, Pancreatic and Liver Transplant Surgeon

PhD FRCS

Prof. Keith Roberts

Consultant Hepatobiliary, Pancreatic and Liver Transplant Surgeon PhD FRCS

PhD FRCS
HCA-Healthcare-UK

Areas of expertise

  • Abnormal liver function tests (LFTs)
  • Epigastric hernia repair surgery
  • Gallbladder cancer treatment
  • Gallbladder removal surgery (cholecystectomy)
  • Incisional hernia repair surgery
HCA-Healthcare-UK

Address

About Prof. Keith Roberts

GMC number: 4634416

Year qualified: 1999

Place of primary qualification: University of Wales

Prof. Keith Roberts is a leading Consultant Liver and Pancreas Surgeon specialising in the diagnosis and surgical management of complex hepatobiliary and pancreatic conditions. He performs complex liver transplant, liver and pancreas surgery, including borderline and locally advanced pancreatic cancer, vena cava surgery, upper abdominal sarcoma and gallbladder surgery.

He qualified in medicine from the University of Wales College of Medicine in 1999 and completed advanced training in general surgery, hepatobiliary and pancreatic surgery, liver transplantation and organ retrieval. He undertook specialist training at St James’s University Hospital in Leeds before joining the hepatobiliary and pancreatic surgery department at the Queen Elizabeth Hospital Birmingham in 2013.

His clinical expertise spans the full range of liver, pancreas, bile duct and gallbladder disease, with particular experience in complex liver and pancreatic surgery. He is recognised for his specialist skills in managing complex disease and has contributed extensively to research across hepatobiliary and pancreatic conditions.

He has led national studies to improve pancreatic cancer care and contributes to shaping liver and pancreas surgery through national protocols, expert guidance and NICE recommendations. His research focuses on improving pancreatic cancer care, treatment and outcomes, including the role of nutrition and gut health.

He is committed to delivering personalised, holistic care, developing pathways that reduce time to treatment and improve patient experience, particularly for patients requiring urgent surgery.

Areas of expertise

  • Bile duct cancer (cholangiocarcinoma)
  • Biliary cancer
  • Biliary stricture
  • Complex liver and pancreatic surgery
  • Gallbladder cancer
  • Gallstones
  • General surgery
  • Hepatobiliary and pancreatic surgery
  • Liver cancer
  • Liver disease
  • Liver metastases
  • Liver transplantation and organ retrieval
  • Neuroendocrine tumours (NETs)
  • Pancreatic cancer
  • Secondary liver cancer

Professional memberships

Pancreatic Society of Great Britain and Ireland
Royal College of Surgeons
Association of Upper Gastrointestinal Surgeons AUGIS
General Medical Council

Articles by Prof. Keith Roberts

Adjuvant chemotherapy after resection of localized pancreatic adenocarcinoma following preoperative folfirinox

Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma

Oncological resection and perioperative outcomes of robotic, laparoscopic and open pancreatoduodenectomy for ampullary adenocarcinoma

Outcome of minimally invasive and open pancreatoduodenectomy in patients with intestinal- and pancreatobiliary subtype ampullary cancer

Failure to rescue after resection of perhilar cholangiocarcinoma in an international multicenter cohort

Management of distal cholangiocarcinoma with arterial involvement

Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentre study

Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy? Results from an international multicentre study

Tackling challenges in rare diseases

Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients